Page last updated: 2024-12-09

1-cyclohexyl-5-(2-phenoxyethylthio)tetrazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1-Cyclohexyl-5-(2-phenoxyethylthio)tetrazole, often abbreviated as **CHPT**, is a chemical compound that has attracted attention for its potential applications in various research areas, particularly in medicine and materials science. Here's a breakdown of the compound and its significance:

**Structure and Properties:**

* **Tetrazole ring:** The core of the molecule is a tetrazole ring, a five-membered heterocyclic ring containing four nitrogen atoms and one carbon atom. Tetrazoles are known for their diverse chemical reactivity and potential for forming stable, nitrogen-rich compounds.
* **Cyclohexyl group:** The cyclohexyl group is a saturated six-membered ring attached to the tetrazole ring at the 1-position. This provides the compound with a hydrophobic character.
* **Phenoxyethylthio group:** The phenoxyethylthio group, attached to the tetrazole ring at the 5-position, introduces an aromatic character and a reactive sulfur atom.

**Importance in Research:**

**1. Medicinal Chemistry:**

* **Antimicrobial Activity:** CHPT has shown promising antimicrobial activity against a range of bacteria, including drug-resistant strains. Its ability to disrupt bacterial cell membranes and interfere with critical metabolic processes makes it a potential candidate for developing new antibiotics.
* **Anti-inflammatory Effects:** Studies suggest that CHPT possesses anti-inflammatory properties. This opens up avenues for its potential use in treating inflammatory conditions such as arthritis and autoimmune disorders.
* **Anticancer Activity:** Preliminary research indicates that CHPT might exhibit anticancer activity by interfering with the growth and proliferation of cancer cells. However, further studies are needed to confirm its efficacy and safety in cancer therapy.

**2. Materials Science:**

* **Organic Electronics:** CHPT's electron-rich nature and its ability to form stable complexes with metal ions make it a potential candidate for use in organic electronics, such as organic light-emitting diodes (OLEDs) and organic field-effect transistors (OFETs).
* **Coordination Chemistry:** CHPT's sulfur atom can coordinate with metal ions, creating coordination complexes with diverse properties. This makes it a potential ligand for use in catalysis and sensor development.

**3. Chemical Synthesis:**

* **Versatile Building Block:** CHPT can serve as a versatile building block for synthesizing new organic compounds with desired biological or material properties. Its unique structure allows for the introduction of various functional groups, expanding its potential applications.

**Ongoing Research:**

While CHPT holds significant promise, research is ongoing to further explore its properties, optimize its synthesis, and evaluate its safety and efficacy in various applications.

**Note:** It's crucial to remember that the potential applications of CHPT are still under investigation, and further research is needed to fully understand its properties and potential benefits.

Cross-References

ID SourceID
PubMed CID653222
CHEMBL ID1559957
CHEBI ID123223

Synonyms (14)

Synonym
1-cyclohexyl-5-(2-phenoxy-ethylsulfanyl)-1h-tetrazole
smr000009920
MLS000031656
STK325286
1-cyclohexyl-5-[(2-phenoxyethyl)sulfanyl]-1h-tetrazole
CHEBI:123223
AKOS000548059
1-cyclohexyl-5-(2-phenoxyethylsulfanyl)tetrazole
HMS2287F09
CHEMBL1559957
Q27212908
1-cyclohexyl-5-(2-phenoxyethylthio)tetrazole
SR-01000317587-1
sr-01000317587
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency7.94330.003245.467312,589.2998AID2517
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency89.12510.631035.7641100.0000AID504339
LuciferasePhotinus pyralis (common eastern firefly)Potency13.62600.007215.758889.3584AID411; AID588342
glp-1 receptor, partialHomo sapiens (human)Potency11.22020.01846.806014.1254AID624417
BRCA1Homo sapiens (human)Potency1.25890.89137.722525.1189AID624202
ATAD5 protein, partialHomo sapiens (human)Potency3.52990.004110.890331.5287AID504466; AID504467
thioredoxin glutathione reductaseSchistosoma mansoniPotency0.89130.100022.9075100.0000AID485364
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency35.48130.707912.194339.8107AID720542
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency25.11890.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency25.11890.001318.074339.8107AID926; AID938
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency50.11870.707936.904389.1251AID504333
P53Homo sapiens (human)Potency56.23410.07319.685831.6228AID504706
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency50.11870.035520.977089.1251AID504332
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency0.56230.01262.451825.0177AID485313
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
flap endonuclease 1Homo sapiens (human)Potency89.12510.133725.412989.1251AID588795
ras-related protein Rab-9AHomo sapiens (human)Potency1.00000.00022.621531.4954AID485297
lethal(3)malignant brain tumor-like protein 1 isoform IHomo sapiens (human)Potency22.38720.075215.225339.8107AID485360
survival motor neuron protein isoform dHomo sapiens (human)Potency11.22020.125912.234435.4813AID1458
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]